Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 55 draft registration and review guidelines for Class II passive medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for non-powered equipment including radioactive seed implantation protective products.

Regulatory Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	55 Guiding Principles for Registration and Review of Class II Passive Medical Devices (Draft for Comments)
Lead guideline	Radioactive Seed Implantation Protective Products Registration and Review Guiding Principles
Total guidelines	55
Product class	Class II passive medical devices
Comment deadline	Oct 8, 2026
Submission	Contact details per attached list

Key Scope

The batch covers registration and review technical standards for 55 categories of Class II passive medical devices—equipment that does not rely on electrical energy or other power sources. The lead document addresses radioactive seed implantation protective products, with the full portfolio spanning diverse non-powered medical equipment categories used in surgical, therapeutic, and diagnostic settings.

Market Impact Analysis

The simultaneous release of 55 draft guidelines represents one of CMDE’s largest standardization efforts for mid-risk passive devices, creating a comprehensive regulatory roadmap for manufacturers navigating China’s Class II registration pathway. For domestic and international device makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, biocompatibility testing, and clinical evidence requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II passive devices—a category that includes wound dressings, surgical instruments, infusion sets, and implantable accessories—signals intensified scrutiny of non-powered devices that are widely used across clinical settings but produced by a fragmented supplier base. The selection of radioactive seed implantation protective products as the lead guideline reflects growing regulatory attention to radiation oncology accessories as brachytherapy expands in China.

Forward-Looking Statement

Industry analysts expect the finalized 55 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II passive device registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new material testing protocols or sterilization validation requirements not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad device portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260901133559138.html

Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 16 draft registration and review guidelines for Class II in vitro diagnostic (IVD) reagents and medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for diagnostic testing products including parathyroid hormone assay reagents.

Regulatory Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	16 Guiding Principles for Registration and Review of Class II In Vitro Diagnostic Reagents and Medical Devices (Draft for Comments)
Lead guideline	Parathyroid Hormone Assay Reagent Registration and Review Guiding Principles
Total guidelines	16
Product class	Class II in vitro diagnostic reagents and medical devices
Comment deadline	Oct 8, 2026
Submission	Contact details per attached list

Key Scope

The batch covers registration and review technical standards for 16 categories of Class II IVD reagents and devices. The lead document addresses parathyroid hormone assay reagents, with the full portfolio spanning diverse diagnostic testing categories.

Market Impact Analysis

The simultaneous release of 16 draft guidelines represents a significant standardization effort for mid-risk diagnostic products, creating a comprehensive regulatory roadmap for IVD manufacturers navigating China’s Class II registration pathway. For domestic and international diagnostic makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, performance evaluation, and clinical evidence requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II IVD reagents—a category that includes immunoassay kits, clinical chemistry reagents, and molecular diagnostic products—signals intensified scrutiny of diagnostic devices that are widely used in clinical laboratories but produced by a fragmented supplier base.

Forward-Looking Statement

Industry analysts expect the finalized 16 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II IVD registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new analytical performance requirements or clinical validation standards not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad diagnostic portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901133826130.html